Hyperosmolar hyperglycemic state
|Hyperosmolar hyperglycemic state|
|Other names: Hyperosmolar hyperglycemic nonketotic coma (HHNC), hyperosmolar non-ketotic coma (HONK), nonketotic hyperosmolar coma, hyperosmolar hyperglycemic nonketotic syndrome (HHNS)|
|Symptoms||Signs of dehydration, altered level of consciousness|
|Complications||Disseminated intravascular coagulopathy, mesenteric artery occlusion, rhabdomyolysis|
|Usual onset||Days to weeks|
|Risk factors||Infections, stroke, trauma, certain medications, heart attacks|
|Diagnostic method||Blood tests|
|Differential diagnosis||Diabetic ketoacidosis|
|Treatment||Intravenous fluids, insulin, low molecular weight heparin, antibiotics|
|Prognosis||~15% risk of death|
Hyperosmolar hyperglycemic state (HHS) is a complication of diabetes mellitus in which high blood sugar results in high osmolarity without significant ketoacidosis. Symptoms include signs of dehydration, weakness, leg cramps, vision problems, and an altered level of consciousness. Onset is typically over days to weeks. Complications may include seizures, disseminated intravascular coagulopathy, mesenteric artery occlusion, or rhabdomyolysis.
The main risk factor is a history of diabetes mellitus type 2. Occasionally it may occur in those without a prior history of diabetes or those with diabetes mellitus type 1. Triggers include infections, stroke, trauma, certain medications, and heart attacks. Diagnosis is based on blood tests finding a blood sugar greater than 30 mmol/L (600 mg/dL), osmolarity greater than 320 mOsm/kg, and a pH above 7.3.
Initial treatment generally consists of intravenous fluids to manage dehydration, intravenous insulin in those with significant ketones, low molecular weight heparin to decrease the risk of blood clotting, and antibiotics among those in whom there is concerns of infection. The goal is a slow decline in blood sugar levels. Potassium replacement is often required as the metabolic problems are corrected. Efforts to prevent diabetic foot ulcers are also important. It typically takes a few days for the person to return to baseline.
While the exact frequency of the condition is unknown, it is relatively common. Older people are most commonly affected. The risk of death among those affected is about 15%. It was first described in the 1880s.
Signs and symptoms
Symptoms of HHS include:
- Altered level of consciousness
- Neurologic signs including: blurred vision, headaches, focal seizures, myoclonic jerking, reversible paralysis
- Motor abnormalities including flaccidity, depressed reflexes, tremors or fasciculations
- Hyperviscosity and increased risk of blood clot formation
- Weight loss
- Nausea, vomiting, and abdominal pain
- Low blood pressure with standing
The main risk factor is a history of diabetes mellitus type 2. Occasionally it may occur in those without a prior history of diabetes or those with diabetes mellitus type 1. Triggers include infections, stroke, trauma, certain medications, and heart attacks.
Other risk factors:
- Lack of sufficient insulin (but enough to prevent ketosis)
- Poor kidney function
- Poor fluid intake (dehydration)
- Older age (50–70 years)
- Certain medical conditions (cerebral vascular injury, myocardial infarction, sepsis)
- Certain medications (glucocorticoids, beta-blockers, thiazide diuretics, calcium channel blockers, and phenytoin)
HHS is usually precipitated by an infection, myocardial infarction, stroke or another acute illness. A relative insulin deficiency leads to a serum glucose that is usually higher than 33 mmol/L (600 mg/dL), and a resulting serum osmolarity that is greater than 320 mOsm. This leads to excessive urination (more specifically an osmotic diuresis), which, in turn, leads to volume depletion and hemoconcentration that causes a further increase in blood glucose level. Ketosis is absent because the presence of some insulin inhibits hormone-sensitive lipase-mediated fat tissue breakdown.
- Plasma glucose level >30 mmol/L (>600 mg/dL)
- Serum osmolality >320 mOsm/kg
- Profound dehydration, up to an average of 9L (and therefore substantial thirst (polydipsia))
- Serum pH >7.30
- Bicarbonate >15 mEq/L
- Small ketonuria (~+ on dipstick) and absent-to-low ketonemia (<3 mmol/L)
- Some alteration in consciousness
- BUN > 30 mg/dL (increased)
- Creatinine > 1.5 mg/dL (increased)
Cranial imaging is not used for diagnosis of this condition. However, if MRI is performed, it may show cortical restricted diffusion with unusual characteristics of reversible T2 hypointensity in the subcortical white matter.
The major differential diagnosis is diabetic ketoacidosis (DKA). In contrast to DKA, serum glucose levels in HHS are extremely high, usually greater than 40-50 mmol/L (600 mg/dL). Metabolic acidosis is absent or mild. A temporary state of confusion (delirium) is also more common in HHS than DKA. HHS also tends to affect older people more. DKA may have fruity breath, and rapid and deep breathing.
DKA often has serum glucose level greater than 300 mg/dL (HHS is >600 mg/dL). DKA usually occurs in type 1 diabetics whereas HHS is more common in type 2 diabetics. DKA is characterized by a rapid onset, and HHS occurs gradually over a few days. DKA also is characterized by ketosis due to the breakdown of fat for energy.
Both DKA and HHS may show symptoms of dehydration, increased thirst, increased urination, increased hunger, weight loss, nausea, vomiting, abdominal pain, blurred vision, headaches, weakness, and low blood pressure with standing.
Treatment of HHS begins with reestablishing tissue perfusion using intravenous fluids. People with HHS can be dehydrated by 8 to 12 liters. Attempts to correct this usually take place over 24 hours with initial rates of normal saline often in the range of 1 L/h for the first few hours or until the condition stabilizes.
Insulin is given to reduce blood glucose concentration; however, as it also causes the movement of potassium into cells, serum potassium levels must be sufficiently high or dangerously low blood potassium levels may result. Once potassium levels have been verified to be greater than 3.3 mEq/l, then an insulin infusion of 0.1 units/kg/hr is started. The goal for resolution is a blood glucose of less than 200 mg/dL.
- "Hyperosmolar Hyperglycemic Nonketotic Syndrome (HHNS)". American Diabetes Association. Archived from the original on 2 July 2012. Retrieved 6 July 2012. CS1 maint: discouraged parameter (link)
- Stoner, GD (1 May 2005). "Hyperosmolar hyperglycemic state". American Family Physician. 71 (9): 1723–30. PMID 15887451.
- Frank, LA; Solomon, A (2 September 2016). "Hyperglycaemic hyperosmolar state". British Journal of Hospital Medicine. 77 (9): C130-3. doi:10.12968/hmed.2016.77.9.C130. PMID 27640667.
- Pasquel, FJ; Umpierrez, GE (November 2014). "Hyperosmolar hyperglycemic state: a historic review of the clinical presentation, diagnosis, and treatment". Diabetes Care. 37 (11): 3124–31. doi:10.2337/dc14-0984. PMC 4207202. PMID 25342831.
- Henry, McMichael (2016). ATI RN Adult Medical Surgical Nursing 10.0. Assessments Technology Institutes. pp. 537–538. ISBN 9781565335653.
- Stoner, GD (May 2005). "Hyperosmolar hyperglycemic state". American Family Physician. 71 (9): 1723–30. PMID 15887451. Archived from the original on 24 July 2008. CS1 maint: discouraged parameter (link)
- Lewis P. Rowland; Timothy A. Pedley (2010). Merritt's Neurology. Lippincott Williams & Wilkins. pp. 369–370. ISBN 978-0-7817-9186-1. Archived from the original on 24 March 2017. CS1 maint: discouraged parameter (link)
- Magee MF, Bhatt BA (2001). "Management of decompensated diabetes. Diabetic ketoacidosis and hyperglycemic hyperosmolar syndrome". Crit Care Clin. 17 (1): 75–106. doi:10.1016/s0749-0704(05)70153-6. PMID 11219236.
- Neuroradiology 2007 Apr;49(4):299-305.
- Tintinalli, Judith E.; Kelen, Gabor D.; Stapczynski, J. Stephan; American College of Emergency Physicians (2004). Emergency Medicine: A Comprehensive Study Guide (6th ed.). McGraw-Hill Prof Med/Tech. p. 1309. ISBN 978-0-07-138875-7. Archived from the original on 24 March 2017. CS1 maint: discouraged parameter (link) CS1 maint: ref=harv (link)
- Tintinalli, Kelen & Stapczynski 2004, p. 1320 harvnb error: no target: CITEREFTintinalliKelenStapczynski2004 (help)
- Tintinalli, Kelen & Stapczynski 2004, p. 1310 harvnb error: no target: CITEREFTintinalliKelenStapczynski2004 (help)